TD Cowen downgraded GlycoMimetics to Hold from Buy without a price target. The analyst cites the “disappointing” Phase III miss for uproleselan in acute myeloid leukemia and the “now much longer timeline” to potential success in the refractory subgroup for the downgrade. The firm says the company’s sickle cell disease program is years away.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLYC: